Choice sees 96% upside in Jeena Sikho as Ayurveda wellness expansion accelerates
Choice Institutional Equities retained its Buy call on Jeena Sikho Lifecare, setting a Rs 1,000 target price versus an assessed Rs 510. The Ayurveda-led healthcare company is targeting 7,000–10,000 beds in three to five years and about 30% annual revenue growth.
What happened
Choice Institutional Equities retained Buy on Jeena Sikho Lifecare, citing its capital-efficient Ayurveda expansion. The company targets 7,000-10,000 beds
Key facts
- Target price: Rs 1,000
- Assessed stock price: Rs 510
- Implied upside: 96%
- Target operational beds: 7,000-10,000
- Guided annual revenue growth: around 30%
Why this matters
Jeena Sikho’s plan to scale to 7,000–10,000 beds while building a 50:50 services-products mix puts execution discipline, clinical capacity and capital efficiency at the center of its Ayurveda wellness expansion.
What to watch
- Quarterly revenue growth versus the stated ~30% target and same-center growth at established facilities.
- Net bed additions, occupancy rates, average revenue per occupied bed, and time required for new centers to break even.
- Progress toward the targeted 50:50 services-products mix, including product gross margin and repeat-order rates.
- Operating cash flow, working-capital intensity, lease liabilities, and any equity or debt financing needed to fund expansion.
- Patient outcomes, reviews, practitioner retention, regulatory notices, and compliance developments affecting wellness or therapeutic claims.